E76.3
Mucopolysaccharidosis, unspecified
Clinical Classification Guidelines
Medical Intelligence & Overview
Mucopolysaccharidosis (MPS) is a group of rare inherited metabolic disorders that affect the body's ability to break down certain complex sugars called mucopolysaccharides or glycosaminoglycans. When these substances are not properly broken down, they accumulate in various tissues and organs, leading to a range of health issues. The classification E76.3 refers to an unspecified form of MPS, meaning specific subtype details are not provided.
Causes & Symptoms
Clinical Causes: Genetic mutations passed from parent to child Deficiency in specific enzymes needed to break down mucopolysaccharides Inheritance pattern usually autosomal recessive, with some exceptions like X-linked forms
Key Symptoms: Coarse facial features such as a broad nose and thick lips Enlarged liver and spleen (hepatosplenomegaly) Joint stiffness and limited range of motion Delayed growth and development Cardiac issues, including heart valve problems Hearing loss or recurrent ear infections Vision problems including clouded corneas Bone deformities and skeletal abnormalities Respiratory difficulties
Diagnostic & Treatment
Diagnosis Path: Diagnosis typically involves a combination of clinical evaluation, patient history, and laboratory tests. Enzyme activity assays are used to measure the levels of specific enzymes involved in mucopolysaccharide breakdown. Genetic testing may be performed to identify mutations. Imaging studies like X-rays can reveal characteristic skeletal abnormalities, and urine tests for excess mucopolysaccharides often support the diagnosis.
Treatment Protocols: While there is no cure for MPS, management focuses on alleviating symptoms and preventing complications. Treatment options include:
Clinical Advice & FAQs
Billing Guidance
Is E76.3 a billable ICD-10 code?
Yes, E76.3 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report E76.3?
Clinical documentation must specify the nature of Mucopolysaccharidosis, unspecified and any associated comorbidities for accurate reporting.
Cite this Clinical Reference